Ameliorating side-effects arising from chemotherapeutic regimen

Project Leader (s):
Anders Ferry

Affiliation:
Dept of Physics, Umeå University

Status:
Active Incubator Project

Brief Description:
Chemotherapy today is a balance of the benefits against the side-effects. While minor side-effects such as hairloss are readily accepted by patients, others are not so benign. A selective reduction of adverse side effects enables the pursuit of more aggressive treatment schedules. This can lead to drastically improved treatment outcomes. We propose a method to selectively reduce side effects caused by methylating agents, such as Temozolomide®, when used to treat neoplasms in the brain. This allows the pursuit of more radical and aggressive treatment schedules.

A single data point (one patient) serves to demonstrate the feasibility of this ameliorative measure to minimize side effects while maximizing treatment efficacy. It is believe that feasibility demonstrate by this project for this example could have broader implications for cancer therapeutics and curative outcomes limited currently by negative side effects.

The project owner believes that is a feasible approach that could extend the utility of some therapies to other patients who show acute sensitivity that limited the chemotherapy to effectively eradicate the cancer.

Intellectual Property Status:
No intellectual property has been formulated yet.

Possible Commercial Potential:
A unique commercial product to ameliorate the side effects of aggressive cancer therapiesContact:
Anders Ferry, Project Contact